1 / 20

Spin-off in Practice: German Biotech Experience from a Polish Perspective

Explore the German biotechnology sector's success in drug development with a focus on the DNAzyme-based therapy for asthma, revealing key development milestones and preclinical programs.

fullmer
Download Presentation

Spin-off in Practice: German Biotech Experience from a Polish Perspective

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Spin-off in practice German experience from Polish perspective Dr. Agnieszka Turowska Warsaw, 2015

  2. Number of companies dedicated to biotechnology: 570 (incl. 13 start ups) • Number of employees in dedicated biotechnology companies 16.950 • Over 90 drugs in clinical trial testing • R&D expenditure of dedicated biotechnology companies 899 Mio.€ • The German Biotechnology Sector 2014 source: Report: The German Biotechnology Sector 2014, biotechnologie.de

  3. 10-15 years for a drug to travel from the research lab to the patient. • 1 to 3 billion euros is the cost of a new drug development from the research lab to the patient • 1 in 10 000 active substances tested in research lab will be placed on the market • Drug development process source: Report: The German Biotechnology Sector 2014, biotechnologie.de

  4. Objective Lead Product Founded in Employees Location Development of novel DNAzyme-based therapies for chronic inflammatory diseases SB010 for moderate and severe Th2-driven asthma 2006 10 Marburg, Germany • sterna biologicals GmbH - Company Overview • Atopic Dermatitis • Ulcerative Colitis • Psoriasis • COPD Further Indications

  5. 1 DNAzymespecificallybindstotargetmRNA DNAzymecleaves GATA-3 mRNA Decompositionofcleavageproducts; DNAzymecontinuescleavageactivity 2 3 • DNAzymes as therapeutic agents ReducedmRNAlevelsresulting in decreaseoftranslatedprotein with subsequent biologicalconsequences

  6. GATA-3 plays a centralrole in theallergicinflammatoryresponse • Orchestrates a widerangeof Th2-mediated cytokines, in particular IL-4, IL-5, IL-9, and IL-13 • Recentevidencethat GATA-3 is also expresseddirectly in Mast cells, Epithelialcells, andEosinophilsfurthersupportscentralroleof GATA-3 • BytargetingGATA-3 directly, SB010 impacts multiple Th2-dependent downstreampathways (“broadspectrum“ approach) • GATA-3 is the Master Transcription Factor • in Th2-driven Inflammatory Diseases Source: Barnes P. JCI 118 (2008): 3546-3556.

  7. Homburg et al. ``Safety and tolerability of a novel inhaled GATA3 mRNA targeting DNAzyme in patients with TH2-driven asthma`` J Allergy Clin Immunol (2015) Turowska et al. ``Biodistribution of the GATA-3-specific DNAzyme hgd40 after inhalative exposure in mice, rats and dogs." Toxicol Appl Pharmacol (2013) Fuhst et al. ``Toxicity profile of the GATA-3-specific DNAzyme hgd40 after inhalation exposure." Pulm Pharmacol Ther. (2013)Dicke et al. "Absence of unspecific innate immune cell activation by GATA-3-specific DNAzymes." Nucleic Acid Ther (2012) Sel et al. "Effective prevention and therapy of experimental asthma using a GATA-3 specific DNAzyme." JACI (2008) Schmidts et al. " Protective effect of drug delivery systems against the enzymatic degradation of dermally applied DNAzyme." Int J Pharm (2011) Schmidts et al. " Development of drug delivery systems for the dermal application of therapeutic DNAzymes." Int J Pharm (2012)

  8. Preclinical program • Toxicology and local tolerability studies • Investigational Medical Product (IMP) • Phase I clinical trial • Phase II clinical trial • Phase III clinical trial • Phase IV clinical trial • Key development milestones for biotech • spin-off company

  9. To know and understand the pathogenesis of the disease • To identify crucial pathways and interfere with them by appling a drug molecule • To demonstrate specificity of the molecule (target regulation) • To proof efficacy in in vitro and in vivo animal model(s) • To determine optimal and minimal effective dose • To determine optimal application regimen • To evaluate uptake, kinetics and distribution • To investigate potential off-target effects • To develop analytical method of drug detection • Time: 1-3 years, outsourcing vs internal development • Preclinical program

  10. Preclinical program • Toxicology and local tolerability studies • Investigational Medical Product (IMP) • Phase I clinical trial • Phase II clinical trial • Phase III clinical trial • Phase IV clinical trial • Key development milestones for biotech • spin-off company

  11. Toxicological program • on the example of SB010 for asthma treatment

  12. Toxicological program • on the example of SB010 for asthma treatment • Certified Good Laboratory Practice (GLP) Facility • Parallel vs. sequential proceeding (risk/benefit ratio) • The number and design of toxicology studies may differ depending on country and regulatory agency • Time: 1-3 years

  13. Preclinical program • Toxicology and local tolerability studies • Investigational Medical Product (IMP) • Phase I clinical trial • Phase II clinical trial • Phase III clinical trial • Phase IV clinical trial • Key development milestones for biotech • spin-off company

  14. GMP (Good Manufacturing Practice) certified manufacturing • Stability studies (min. 6 months) • Certified Packaging • Transport & distribution • Investigational Medical Product (IMP)

  15. Preclinical programm • Toxicology and local tolerability studies • Investigetional Medical Product (IMP) • Phase I clinical trial • Phase II clinical trial • Phase III clinical trial • Phase IV clinical trial • Key development milestones for biotech • spin-off company

  16. Phase I clinical trial Primary goal: safety & tolerabilty (20-80 subjects, weeks to months) • Clinical Trial Overview First in class First in man I a: safety & tolerability [single dose, healthy subjects] I b: safety & tolerability [multiple doses, healthy subjects] I c: safety & tolerability [single dose, patients] • Phase II clinical trial • Primary goal: efficacy & safety (30 -200 patients, months to years) First in class II a: explorative POC study [multiple dose, patients] II b. Proof of concept study [multiple ascending dose, patients] • The number and design of clinical trials may vary depending on country and regulatory agency

  17. Preclinical program • Toxicology and local tolerability studies • Investigational Medical Product (IMP) • Phase I clinical trial • Phase II clinical trial • Phase III clinical trial • Phase IV clinical trial • Key development milestones for biotech • spin-off company value risk quality requirements Is it realistic for academic spin-off to place the drug on the market?

  18. Scientific publications • Conference presentations & posters • Reports from preclinical and toxicological studies a including raw data • Documents submitted to regulatory agencies: Investigator´s Brochure (IB), clinical trial protocol, Investigational Medical Product Dossier (IMPD) • Audit reports of the external collaborators • SOP (Standard Operating Procedure) process overview • Evaluation criteria

  19. The goal & destination of academic spin-off should be defined at the beginning based on: human resources, financial status, potential of research facility • Interaction with business partners is inscribed in the nature of academic spin-off • Therefore, quality standards required by business partners have to be fullfilled (or exceeded!) in order to ensure collaboration and secure seed financing • Meeting quality standards in practice means that the structure of academic spin-off should be carefully designed (professional writer & quality control, GLP) • Summary

  20. Thank you

More Related